Oral solid preparation of escitalopram oxalate and preparation method thereof

Abstract

The invention discloses an oxalic acid esmolol citalopram oral solid preparation and a preparation method. The oral solid preparation comprises raw materials of: 2-40 parts by weight of oxalic acid esmolol citalopram, 5-60 parts by weight of starch, 5-200 parts by weight of microcrystalline cellulose, 5-60 parts by weight of lactose, 0.05-5 parts by weight of binding agent and 0.05-3 parts by weight of lubricant; the binding agent is one or a plurality of mixed aqueous solutions or alcoholic solutions from the group consisting of polyvinyl pyrrolidone, hydroxyethyl methylcellulose, methylcellulose, hydroxypropyl cellulose and ethyl cellulose, the concentration of the binding agent is 0.1-10.0%; and the lubricant is stearic acid, magnesium stearate, calcium stearate, talcum or superfine silica gel powder.

Description

field of invention

[0001] The invention relates to a medicine, in particular to an oral solid preparation of escitalopram oxalate and a preparation method thereof. Background technique

[0002] Escitalopram oxalate is an oral selective serotonin reuptake inhibitor (SSRI). Escitalopram oxalate is the S-isomer (single isomer) of racemic citalopram. Jointly developed by Forest Laboratories and Lundbeck, Denmark.

[0003] Citalopram, manufactured by Forest Laboratories, has been sold as an antidepressant under various trade names (including Celexa, Cipramil, and Seropram) in 70 countries since its approval date of July 17, 1998. Since then, the company has submitted a new drug application for escitalopram to the US Food and Drug Administration (FDA), using escitalopram for the treatment of depression; it was approved on November 27, 2002.

[0004] The Phase III clinical trial results of Forest Experimental Company's new antidepressant escitalopram showed that compared with ci...

Images